소아 의료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pediatric healthcare market size was valued at USD 15.93 billion in 2025 and estimated to grow from USD 16.53 billion in 2026 to reach USD 19.90 billion by 2031, registering a 3.78% CAGR between 2026 and 2031.

This report is Segmented by Product Type (Pharmaceuticals, Vaccines, and More), Therapeutic Area (Infectious Diseases, Respiratory Disorders, and More), Age Group (Neonates, Infants, and More), Care Setting (Hospitals, Clinics, and More), End User (Public Healthcare Providers and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Pediatric Healthcare Market Trends and Insights

Routine Pediatric-Immunization Funding Momentum

Record sums are flowing into childhood immunization schedules. GAVI allocated USD 9 billion for 2024-2025 to subsidize HPV, pneumococcal conjugate, and rotavirus vaccines, assuring manufacturers of multi-year demand. In the United States, the Vaccines for Children program distributed 84 million doses in 2024, 6% above 2023 volumes, as catch-up campaigns recaptured pandemic-era defaulters. Guaranteed procurement compresses time-to-market for combination vaccines, yet the infectious-disease focus crowds out research on adolescent-specific shots for non-communicable threats. Manufacturers now aim to bundle multiple antigens to maximize throughput on established filling lines, a strategy that also reduces cold-chain burden. Still, divergent political attitudes toward mandates in some regions limit the penetration of newly recommended vaccines.

Gene-Therapy Approvals for Rare Pediatric Diseases

Five pediatric gene therapies were approved in 2024-2025, each priced above USD 2 million per patient, shifting conversations from dose-based billing to milestone-based contracts. Surrogate endpoints, such as enzyme activity, enable earlier launches, enticing venture capital into next-generation vectors. Accelerated pathways shave 18-24 months off development cycles, but questions remain on durability and equitable rollout in middle-income markets that lack long-term monitoring infrastructure. Hospitals must upgrade virology suites to handle on-site reconstitution, and payers are layering annuity payments over five years to hedge therapeutic uncertainty. The Pediatric healthcare market is poised to absorb more one-time curative modalities as manufacturing yields climb.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Assisted Pediatric Radiology Adoption
2. Re-Emergence of RSV and Other Respiratory Outbreaks
3. Rising Antimicrobial Resistance in Children
4. Shortage of Pediatric Subspecialists in Low-Income Regions

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Vaccines accounted for 38.55% of 2025 revenue, anchoring the Pediatric healthcare market through stable procurement tied to national schedules. The Pediatric healthcare market size for digital health solutions is projected to advance at a 5.25% CAGR, the fastest among categories, as payers accept that remote monitoring curbs costly admissions. Pharmaceutical revenues grow modestly because biosimilar erosion offsets gains from orphan drugs. Device makers benefit from miniaturization, translating adult inventions into child-sized form factors that drive adherence. Services revenue spans inpatient care, outpatient consults, and expanding home health visits, optimized by virtual check-ins.

Digital platforms embed AI to flag deteriorating vitals, allowing clinicians to intervene before crises. FDA clearance of Canvas Dx for early autism screening showed regulators' willingness to back algorithmic assessments. Vaccines for emerging pathogens will deliver incremental gains, but finite schedules cap upside. Manufacturers respond with multivalent formulations that free clinic slots and attract bundled tenders. Overall, the Pediatric healthcare market continues to balance preventive biologics with technology-enabled chronic-care management.

Infectious diseases comprised 33.53% of therapeutic spending in 2025, driven by respiratory and vaccine-preventable illnesses. Oncology is on track for a 4.75% CAGR through 2031, driven by CAR-T therapies and earlier tumor detection enabled by expanded newborn screening. Respiratory disorders benefit from monoclonals that extend dosing intervals, while neurological portfolios grow as gene therapies target intractable epilepsies. Cardiovascular interventions shift toward catheter-based repairs, reducing hospital days.

The Pediatric healthcare market for oncology will expand as more solid-tumor cell therapies, such as afamitresgene autoleucel, reach adolescents. Yet capacity constraints for apheresis and cytokine-management beds could bottleneck penetration. Infectious-disease allocations may fall marginally as RSV prophylaxis dampens hospital costs, but persistent funding for routine vaccines keeps the category atop spending tables.

Complete Report Scope:

• By Product Type
  • Pharmaceuticals
  • Vaccines
  • Medical Devices
  • Digital Health Solutions
• By Therapeutic Area
  • Infectious Diseases
  • Respiratory Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Oncology
  • Gastro-intestinal Disorders
• By Age Group
  • Neonates (0-28 days)
  • Infants (1-23 months)
  • Children (2-11 years)
  • Adolescents (12-18 years)
• By Care Setting
  • Hospitals
  • Clinics
  • Homecare
  • Telehealth
• By End User
  • Public Healthcare Providers
  • Private Healthcare Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 35.23% of global revenue in 2025, driven by high per-capita outlays and a dense network of children's hospitals. Value-based contracts are nudging providers toward preventive interventions that curb emergency utilization. The Pediatric healthcare market in the region is expected to grow steadily as gene therapies debut at flagship centers, though payer scrutiny of million-dollar price tags intensifies.

Asia-Pacific will record a 6.12% CAGR to 2031 as China and India expand pediatrician pipelines and upgrade county-level hospitals. Middle-class demand for premium care sparks joint ventures with multinational device makers that localize production to sidestep tariffs. In Southeast Asia, micro-insurers bundle telehealth consults with wellness apps, widening access among gig-economy workers.

Europe enjoys universal coverage but faces stalling birth rates in Germany and Italy, tempering volume growth. Still, EU funds are modernizing neonatal ICUs in Eastern states, narrowing East-West equipment gaps. In the Middle East, Gulf states allocate hydrocarbon windfalls to pediatric care hubs to attract medical tourism. Africa's fragmented infrastructure limits reach, yet pilot drone networks now ferry vaccines to remote clinics, inching coverage upward.

1. Abbott Laboratories
2. AstraZeneca
3. Cardinal Health
4. Dr. Reddy's Laboratories Ltd.
5. Roche
6. Fresenius
7. GE HealthCare Technologies Inc.
8. GlaxoSmithKline
9. Johnson & Johnson
10. Koninklijke Philips
11. Medtronic
12. Merck
13. Novartis
14. Pfizer
15. Sanofi
16. Siemens Healthineers
17. Takeda Pharmaceuticals
18. Teladoc Health

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Routine Pediatric-Immunization Funding Momentum
  • 4.2.2 Gene-Therapy Approvals for Rare Pediatric Diseases
  • 4.2.3 AI-Assisted Pediatric Radiology Adoption
  • 4.2.4 Re-Emergence of RSV and Other Respiratory Outbreaks
  • 4.2.5 School-Based Telehealth Roll-Outs
  • 4.2.6 Micro-Hospital Formats For Children
• 4.3 Market Restraints
  • 4.3.1 Rising Antimicrobial Resistance in Children
  • 4.3.2 Gap in Pediatric-Specific Device Reimbursement
  • 4.3.3 Dearth of Long-Term Safety Data for mRNA Vaccines
  • 4.3.4 Shortage of Pediatric Subspecialists in Low-Income Regions
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Bargaining Power of Buyers
  • 4.6.2 Bargaining Power of Suppliers
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Pharmaceuticals
  • 5.1.2 Vaccines
  • 5.1.3 Medical Devices
  • 5.1.4 Digital Health Solutions
• 5.2 By Therapeutic Area
  • 5.2.1 Infectious Diseases
  • 5.2.2 Respiratory Disorders
  • 5.2.3 Neurological Disorders
  • 5.2.4 Cardiovascular Disorders
  • 5.2.5 Oncology
  • 5.2.6 Gastro-intestinal Disorders
• 5.3 By Age Group
  • 5.3.1 Neonates (0-28 days)
  • 5.3.2 Infants (1-23 months)
  • 5.3.3 Children (2-11 years)
  • 5.3.4 Adolescents (12-18 years)
• 5.4 By Care Setting
  • 5.4.1 Hospitals
  • 5.4.2 Clinics
  • 5.4.3 Homecare
  • 5.4.4 Telehealth
• 5.5 By End User
  • 5.5.1 Public Healthcare Providers
  • 5.5.2 Private Healthcare Providers
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 AstraZeneca plc
  • 6.3.3 Cardinal Health, Inc.
  • 6.3.4 Dr. Reddy's Laboratories Ltd.
  • 6.3.5 F. Hoffmann-La Roche Ltd
  • 6.3.6 Fresenius Medical Care AG & Co. KGaA
  • 6.3.7 GE HealthCare Technologies Inc.
  • 6.3.8 GSK plc
  • 6.3.9 Johnson & Johnson
  • 6.3.10 Koninklijke Philips N.V.
  • 6.3.11 Medtronic plc
  • 6.3.12 Merck & Co., Inc.
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Sanofi S.A.
  • 6.3.16 Siemens Healthineers AG
  • 6.3.17 Takeda Pharmaceutical Company Ltd.
  • 6.3.18 Teladoc Health, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment